DDInter1928 DDInter899
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Verapamil {u} (Compound) resembles {v} (Compound) Bevantolol
Verapamil {u} (Compound) resembles {v} (Compound) Trimethobenzamide
Verapamil {u} (Compound) treats {v} (Disease) migraine
Verapamil {u} (Compound) binds {v} (Gene) CACNB2
Verapamil {u} (Compound) upregulates {v} (Gene) MCOLN1
Verapamil {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Verapamil {u} (Compound) downregulates {v} (Gene) DNAJA3
Verapamil {u} (Compound) causes {v} (Side Effect) Diarrhoea
Verapamil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Verapamil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Verapamil (Compound) resembles Bevantolol (Compound)
Verapamil (Compound) resembles Trimethobenzamide (Compound)
Verapamil (Compound) treats migraine (Disease)
Verapamil (Compound) binds CACNB2 (Gene)
Verapamil (Compound) upregulates MCOLN1 (Gene)
Verapamil (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class)
Verapamil (Compound) downregulates DNAJA3 (Gene)
Verapamil (Compound) causes Diarrhoea (Side Effect)
Verapamil may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Verapamil may cause a minor interaction that can limit clinical effects when taken with Bexarotene